Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
UNIVERSITE DE GENEVE has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These are in 3 distinct art units. This spread suggests that the university's research covers multiple specialized fields within the broader biotechnology sector. Having 3 different administrative groups review the cases requires a prosecution strategy that accounts for varying standards and prior art landscapes. Practitioners must tailor their approach to the specific requirements of each of the 3 units involved to ensure consistent progress. This distribution across 3 units indicates a breadth of technical subject matter.
3 distinct examiners are reviewing the cases. GALSTER, SAMUEL LEONARD is the busiest with 1 pending office action. This distribution means that the workload is split between different individuals. The university must navigate the individual styles and interpretations of 3 different people across the 3 units. The prosecution strategy should involve monitoring the feedback from all officials to identify unique challenges in the Biotechnology & Pharmaceuticals sector. Success requires a balanced approach to satisfy GALSTER, SAMUEL LEONARD and the other assigned examiners while managing 3 separate prosecution tracks.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
| MARTIN, PAUL C | 1 | 41.8% | +21.7% |
| SABILA, MERCY HELLEN | 1 | 57.5% | +45.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17761626 | CELLULAR SUBSTITUTES AND METHODS OF PREPARATION THEREOF | MARTIN, PAUL C | 86d overdue |
| 18682951 | [1,2,4]TRIAZOLO[4,3-A]PYRIMIDIN-7(8H)-ONE AS MITOCHONDRIAL PYRUVATE CARRIER INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GALSTER, SAMUEL LEONARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17761626 | CELLULAR SUBSTITUTES AND METHODS OF PREPARATION THEREOF | MARTIN, PAUL C | 86d overdue |
| 18682951 | [1,2,4]TRIAZOLO[4,3-A]PYRIMIDIN-7(8H)-ONE AS MITOCHONDRIAL PYRUVATE CARRIER INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GALSTER, SAMUEL LEONARD | — |
| 17617241 | COMPOSITIONS FOR USE IN THE TREATMENT OF INSULIN DEFICIENCY CONDITIONS | SABILA, MERCY HELLEN | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1653 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682951 | [1,2,4]TRIAZOLO[4,3-A]PYRIMIDIN-7(8H)-ONE AS MITOCHONDRIAL PYRUVATE CARRIER INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GALSTER, SAMUEL LEONARD | 1693 | §102§103§112 | Non-Final OA | — | Pending | Feb 12, 2024 |
| 17761626 | CELLULAR SUBSTITUTES AND METHODS OF PREPARATION THEREOF | MARTIN, PAUL C | 1653 | §103§112 | Non-Final OA | 86d overdue | Pending | Mar 18, 2022 |
| 17617241 | COMPOSITIONS FOR USE IN THE TREATMENT OF INSULIN DEFICIENCY CONDITIONS | SABILA, MERCY HELLEN | 1654 | §103 | Final Rejection | — | Pending | Dec 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE DE GENEVE has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Samuel Leonard Galster has the most, with 1 of UNIVERSITE DE GENEVE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
